{"blog": [], "keywords": [{"value": "Initial Public Offerings", "name": "subject", "rank": "1", "is_major": "N"}, {"value": "Beigene Ltd.", "name": "organizations", "rank": "2", "is_major": "N"}, {"value": "Editas Medicine Inc", "name": "organizations", "rank": "3", "is_major": "N"}, {"value": "Genetics and Heredity", "name": "subject", "rank": "4", "is_major": "N"}, {"value": "Biotechnology and Bioengineering", "name": "subject", "rank": "5", "is_major": "N"}], "web_url": "http://www.nytimes.com/2016/02/04/business/dealbook/editas-medicine-and-beigene-gain-in-market-debuts.html", "document_type": "article", "byline": {"person": [{"lastname": "PICKER", "firstname": "Leslie", "role": "reported", "organization": "", "rank": 1}], "original": "By LESLIE PICKER"}, "type_of_material": "News", "multimedia": [], "section_name": "Business Day", "word_count": "379", "source": "The New York Times", "subsection_name": "DealBook", "lead_paragraph": "The two biotech companies\u2019 initial public offerings are testing the waters after a recent sell-off in biotech.", "pub_date": "2016-02-04T00:00:00Z", "news_desk": "Business", "headline": {"main": "Editas Medicine and BeiGene Gain in Market Debuts"}, "print_page": null, "snippet": "The two biotech companies\u2019 initial public offerings are testing the waters after a recent sell-off in biotech.", "_id": "56b23fb338f0d82036f0a7aa", "slideshow_credits": null, "abstract": null}